Theralase Technologies Inc.

Ondine Biomedical Inc., a life sciences firm, specializes in the research, development, and commercialization of advanced antimicrobial photodisinfection therapies, operating both within Canada and internationally. Its foundational technology is Photodisinfection, a state-of-the-art, light-based topical antimicrobial approach designed to neutralize detrimental pathogens. The company's flagship product, Steriwave, is a medical device leveraging photodisinfection to eradicate harmful nasal pathogens, thereby significantly mitigating healthcare-acquired infections. Furthermore, Ondine Biomedical's development pipeline includes a topical antiviral treatment for the upper respiratory tract aimed at reducing SARS-CoV-2 viral load and transmission; a solution for addressing chronic rhinosinusitis; OND1002, an agent for disinfecting endotracheal tubes to decrease the occurrence of ventilator-associated pneumonia; and OND1003, formulated for the decolonization of burns and wounds. Established in 1996, the company maintains its corporate headquarters in Vancouver, Canada.

Vector Science and Therapeutics Corp.PAIN · BiotechCanada

62% matchPublic

Vector Science and Therapeutics Corp. is a medical technology and therapeutic delivery company that develops and sells biomechanical devices and active localized drug delivery platforms. Headquartered in Mequon, Wisconsin, the company focuses on providing clinicians with non-systemic, site-directed technologies. It is publicly listed on the TSXV under the ticker PAIN.V.

VaxxasBiotechnologyAustralia

62% match

Vaxxas is a clinical-stage biotechnology company headquartered in Brisbane, Australia. It is commercializing a novel vaccination technology designed to enhance the performance of existing and next-generation vaccines, and opened a biomedical manufacturing facility in Brisbane in June 2023.

Oleander Medical Technologies LLCBiotechnologyUnited States

61% matchPrivate

Oleander Medical Technologies is developing a cancer treatment called Targeted Osmotic Lysis (TOL), which destroys malignant cells by forcing them to absorb excessive sodium and burst. The therapy combines an existing heart medication with an investigational pulsed electric field device to target cancers with elevated sodium channel expression while leaving healthy cells unharmed.

KORTUC USA INC.BiotechnologyUnited States

61% match

Kortuc Inc. develops cancer radiotherapy solutions, specifically offering an innovative radiosensitizer designed to eliminate tumor hypoxia and maximize the effectiveness of radiation treatment. The company serves the medical and oncology research sectors by advancing clinical trials and expanding treatment options for cancer patients.

Nuo Therapeutics, Inc. operates as a regenerative medicine company, specializing in the development, commercialization, and marketing of advanced cell-based technologies. These solutions are engineered to leverage the human body's inherent capacity for natural healing, with a primary focus on the United States market. Central to their offerings is a technology that isolates components from a patient's own blood (autologous) to generate a platelet-based therapy, specifically tailored for the treatment of chronic wounds. Established in Houston, Texas, in 1998, the company underwent a name change from Cytomedix, Inc. to Nuo Therapeutics, Inc. in November 2014.